Currently, there are 7.21M common shares owned by the public and among those 7.10M shares have been available to trade.
The company’s stock has a 5-day price change of 46.96% and 135.70% over the past three months. POAI shares are trading 106.10% year to date (YTD), with the 12-month market performance down to -35.62% lower. It has a 12-month low price of $0.55 and touched a high of $3.06 over the same period. POAI has an average intraday trading volume of 2.20 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 38.84%, 25.53%, and 65.20% respectively.
Institutional ownership of Predictive Oncology Inc (NASDAQ: POAI) shares accounts for 3.34% of the company’s 7.21M shares outstanding.
It has a market capitalization of $12.18M and a beta (3y monthly) value of 1.26. The earnings-per-share (ttm) stands at -$3.06. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.12% over the week and 10.30% over the month.
Analysts forecast that Predictive Oncology Inc (POAI) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0. Earnings per share for the fiscal year are expected to increase by 40.23%, and 93.75% over the next financial year.
Looking at the support for the POAI, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on August 19, 2024, with the firm’s price target at $3.
